# Bayer

Source: https://nuclide.cc/companies/bayer/  
Nuclide record `bayer` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Bayer owns Xofigo, the only approved alpha emitter, and is developing next-generation actinium PSMA agents.

## Summary

Bayer, based in Leverkusen and listed as BAYN.DE, owns Xofigo, or radium-223, the only approved alpha emitter, and is developing next-generation actinium-225 PSMA agents. Its oncology portfolio includes 225Ac-PSMA-Trillium, also known as BAY 3563254, darolutamide in prostate cancer, sevabertinib for HER2-mutant non-small-cell lung cancer approved in 2025, larotrectinib, developed earlier with Lilly, and copanlisib, with the AlphaBreak and AcTION actinium trials linked in Nuclide. Nuclide also connects it to colorectal, liver, GIST and desmoid tumour pages, to the Norwegian Radium Hospital in Oslo, and to its venture arm Leaps by Bayer. Whether a targeted alpha emitter can go further than radium-223 did is the open question its PSMA programme will answer. Actinium-225 PSMA agents have their own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Leverkusen
- Type: pharma
- Website: https://www.bayer.com
- Ticker: BAYN.DE

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Bayer
- Official website: https://www.bayer.com

## Connected records

- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/), [Radium-223](https://nuclide.cc/isotopes/ra-223/)
- drugs: [Actinium-225 PSMA agents](https://nuclide.cc/drugs/ac225-psma/), [Radium-223 dichloride](https://nuclide.cc/drugs/radium-223/), [Sorafenib](https://nuclide.cc/drugs/sorafenib/)
- indications: [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/), [Osteosarcoma](https://nuclide.cc/indications/osteosarcoma/), [Prostate cancer](https://nuclide.cc/indications/prostate/), [Thyroid cancer](https://nuclide.cc/indications/thyroid/)
- technologies: [Actinium-225 supply: thorium stocks, accelerators and radium targets](https://nuclide.cc/technologies/actinium-225-supply/), [Radiopharmaceutical GMP and releasing a drug that decays](https://nuclide.cc/technologies/radiopharmaceutical-gmp-release/)
- institutions: [Oslo University Hospital, The Norwegian Radium Hospital](https://nuclide.cc/institutions/oslo-radium-hospital/)
- trials: [AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)](https://nuclide.cc/trials/alphabreak/)
- bottlenecks: [Actinium-225 supply](https://nuclide.cc/bottlenecks/b-ac225-supply/)
- fronts: [Bone-targeted radiopharmaceuticals](https://nuclide.cc/fronts/f-bone-targeted/)

---
JSON: https://nuclide.cc/api/v1/entities/bayer.json